It should also significantly reduce the risk of long-Covid, as a US study with almost 10,000 patients showed.
For the work, data from the US Veterans Welfare Service were examined. The information of more than 9,000 Covid-19 patients with at least one risk factor (e.g. obesity, diabetes, etc.) for a severe course of the disease was taken from their registers. All had been treated with Paxlovid within five days of confirmed SARS-CoV-2 infection. The information from around 47,000 comparable people without Paxlovid therapy served as the control group.
death rate halved
The result: Compared to the control group, Paxlovid reduced the incidence of long-Covid by 26 percent – including ten out of twelve long-term complications such as heart disease, bleeding disorders, pulmonary thrombosis, exhaustion, liver or kidney disease, muscle pain, cognitive disorders and shortness of breath.
The death rate (all causes) was also reduced by almost half (down 48 percent) among those treated with Paxlovid over the 90-day follow-up period. There was a 30 percent reduction in hospital admissions for any reason.
Source: Nachrichten
